Article Figures & Tables
Figures
- Figure 1:
Number of patients admitted to Jewish General Hospital from Mar. 4 to June 30, 2020, by week, stratified by those living and not living in a residential care facility (RCF) before admission.
- Figure 2:
Kaplan–Meier curve of time to death after hospital admission of patients living and not living in a residential care facility (RCF) before admission. Log-rank test between RCF and non-RCF p < 0.0001.
Tables
- Table 1:
Characteristics of patients admitted to hospital with SARS-CoV-2 infection at time of admission
Variable No. (%) of patients*
n = 656Age, yr, mean ± SD 72.9 ± 18.3 Age group, yr < 50 73 (11.1) 50–59 85 (13.0) 60–69 71 (10.8) 70–79 125 (19.1) ≥ 80 302 (46.0) Sex, female 349 (53.2) Length of symptoms, d, median (IQR) (n = 550) 6.0 (3.0–10.0) Level of intervention (n = 645) 1 304 (47.1) 2 55 (8.5) 3 214 (33.2) 4 72 (11.2) Patients not living in residential care 353 (53.8) Patients living in residential care 303 (46.2) Public long-term care facilities 153 (23.3) Private residential care facilities 105 (16.0) Public intermediate care facilities 45 (6.9) No. of comorbidities 0 103 (15.7) 1 120 (18.3) 2 145 (22.1) 3 111 (16.9) ≥ 4 177 (27.0) Comorbidities (n = 655) Hypertension 399 (60.9) Coronary artery disease 122 (18.6) Congestive heart failure 64 (9.8) Diabetes 183 (27.9) Asthma 50 (7.6) COPD 100 (15.3) Dementia 209 (31.9) Symptoms on admission Presence of fever, cough or URTI 422 (64.3) Fever (n = 654) 358 (54.7) Cough (n = 652) 353 (54.1) Dyspnea (n = 653) 355 (54.4) URTI (n = 651) 58 (8.9) Myalgias (n = 651) 69 (10.6) Fatigue (n = 651) 194 (29.8) Diarrhea (n = 651) 112 (17.2) Vitals on admission Tachycardia (heart rate > 100) (n = 653) 142 (21.7) Tachypnea (respiratory rate > 20) (n = 633) 445 (70.3) Temperature > 38.0°C (n = 611) 151 (24.7) Hypoxemia (O2 < 88% or FiO2 > 0.21) (n = 652) 240 (36.8) Laboratory values WBC, × 109/L, median (IQR) (n = 652) 6.9 (5.0–9.6) Lymphocyte count, × 109/L, median (IQR) (n = 652) 1.0 (0.7–1.4) Lymphopenia (n = 652) 296 (45.4) Platelets, × 109/L, median (IQR) (n = 652) 204.0 (159.5–268.5) Creatinine, μmol/L, median (IQR) (n = 636) 85.5 (67.5–118.0) ALT, U/L, median (IQR) (n = 600) 23.0 (15.0–37.0) Procalcitonin, μg/L median (IQR) (n = 534) 0.1 (0.1–0.3) LDH, U/L, median (IQR) (n = 547) 324.0 (251.0–416.0) D-dimer, μg/L FEU, median (IQR) (n = 482) 1071 (604.0–1773) IL-6, ng/mL, median (IQR) (n = 286) 39.6 (18.4–74.4) Note: ALT = alanine aminotransferase, COPD = chronic obstructive pulmonary disease, FEU = fibrinogen equivalent units, IL6 = interleukin-6, IQR = interquartile range, LDH = lactate dehydrogenase, SD = standard deviation, URTI = symptoms of upper respiratory tract infection, WBC = white blood count.
↵* Unless indicated otherwise.
- Table 2:
Characteristics and outcomes of patients admitted to hospital with SARS-CoV-2 infection, stratified by whether or not they live in residential care facilities
Variable No. (%) of patients from RCFs*
n = 303No. (%) of patients not from RCFs*
n = 353Age, yr, mean ± SD 83.7 ± 11.0 63.7 ± 18.3 Age group, yr < 50 2 (0.7) 71 (20.1) 50–59 10 (3.3) 75 (21.2) 60–69 17 (5.6) 54 (15.3) 70–79 51 (16.8) 74 (21.0) ≥ 80 223 (73.6) 79 (22.4) Sex, female 182 (60.1) 167 (47.3) Length of symptoms, d, median (IQR) (n = 550) 4.0 (2.0–8.0) 7.0 (4.0–11.0) Level of intervention (n = 645) 1 47 (15.6) 257 (74.7) 2 31 (10.3) 24 (7.0) 3 166 (55.1) 48 (14.0) 4 57 (18.9) 15 (4.4) No. of comorbidities 0 8 (2.6) 95 (26.9) 1 39 (12.9) 81 (22.9) 2 71 (23.4) 74 (21.0) 3 63 (20.8) 48 (13.6) ≥ 4 122 (40.3) 55 (15.6) Dementia at admission 188 (62.0) 21 (5.9) Presence of fever, cough or URTI at admission 170 (56.1) 252 (71.4) Hypoxemia (n = 652) at admission 121 (39.9) 119 (34.1) Hospital course ICU admission 14 (4.6) 104 (29.5) Intubated (n = 132) 3 (12.5) 66 (61.1) Length of intubation, d, median (IQR) (n = 56) 9.5 (4.0–15.0) 12.5 (8.0–18.0) Length of ICU stay, d, median (IQR) (n = 117) 4.5 (2.0–15.0) 11.0 (5.0–19.0) Length of hospital stay (overall), d, median (IQR) (n = 647) 14.0 (7.0–26.0) 9.0 (5.0–20.0) Length of hospital stay (survivor), d, median (IQR) (n = 491) 20.0 (10.0–31.0) 9.0 (5.0–20.0) Complications in hospital Acute respiratory distress syndrome (n = 654) 28 (9.2) 69 (19.7) Venous thrombotic events† (n = 654) 9 (3.0) 21 (6.0) Acute kidney injury (n = 626) 60 (20.3) 51 (15.5) Dialysis (n = 654) 0 (0.0) 15 (4.3) Liver enzyme abnormalities (n = 653) 16 (5.3) 61 (17.4) Disposition at discharge Discharged 190 (62.7) 302 (85.6) Death 111 (36.6) 45 (12.7) Still admitted 2 (0.7) 6 (1.7) Time to death, d, median (IQR) (n = 156) 9.0 (5.0–14.0) 11.0 (6.0–23.0) - Table 3:
Characteristics and outcomes of patients admitted to hospital with SARS-CoV-2 infection, stratified by disposition
Variable No. (%) of patients* Total
n = 656Died
n = 156Discharged
n = 492Age group, yr < 50 73 (11.1) 0 (0.0) 72 (14.6) 50–59 85 (13.0) 8 (5.1) 77 (15.7) 60–69 71 (10.8) 9 (5.8) 61 (12.4) 70–79 125 (19.1) 25 (16.0) 98 (19.9) ≥ 80 302 (46.0) 114 (73.1) 184 (37.4) Sex, female 349 (53.2) 70 (44.9) 275 (55.9) Level of intervention (n = 645) 1 304 (47.1) 9 (5.8) 291 (60.5) 2 55 (8.5) 15 (9.6) 39 (8.1) 3 214 (33.2) 65 (41.7) 147 (30.6) 4 72 (11.2) 67 (42.9) 4 (0.8) Patients not living in residential care 353 (53.8) 45 (28.8) 302 (61.4) Patients living in residential care 303 (46.2) 111 (71.2) 190 (38.6) Public long-term care facilities 153 (23.3) 54 (34.6) 98 (19.9) Private residential care facilities 105 (16.0) 41 (26.3) 63 (12.8) Public intermediate care facilities 45 (6.9) 16 (10.3) 29 (5.9) No. of comorbidities 0 103 (15.7) 4 (2.6) 97 (19.7) 1 120 (18.3) 17 (10.9) 101 (20.5) 2 145 (22.1) 35 (22.4) 108 (22.0) 3 111 (16.9) 32 (20.5) 78 (15.9) ≥ 4 177 (27.0) 68 (43.6) 108 (22.0) Presence of fever, cough or URTI at admission 422 (64.3) 108 (69.2) 309 (62.8) Hypoxemia (n = 652) 240 (36.8) 90 (57.7) 148 (30.3) Length of symptoms, d, median (IQR) (n = 550) 6.0 (3.0–10.0) 4.0 (2.0–7.0) 7.0 (3.0–10.0) Hospital course and outcome ICU admission 118 (18.0) 26 (16.7) 89 (18.1) Intubated (n = 132) 69 (52.3) 17 (51.5) 49 (51.0) Length of intubation, d, median (IQR), (n = 56) 12.5 (8.0–17.5) 5.0 (2.5–9.5) 12.0 (9.0–15.0) Length of ICU stay, d, median (IQR), (n = 117) 11.0 (4.0–18.0) 9.0 (3.0–18.0) 11.0 (5.0–17.0) Length of hospital stay, d, median (IQR), (n = 647) 11.0 (6.0–23.0) 9.0 (5.0–16.0) 12.0 (6.0–25.0) Complications in hospital Acute respiratory distress syndrome (n = 654) 97 (14.8) 43 (27.7) 51 (10.4) Venous thrombotic events† (n = 654) 30 (4.6) 3 (1.9) 26 (5.3) Acute kidney injury (n = 626) 111 (17.7) 54 (35.1) 55 (11.8) Liver enzyme abnormalities (n = 653) 77 (11.8) 16 (10.3) 60 (12.2) - Table 4:
Crude and adjusted Cox proportional hazards models with risk factors for in-hospital death among patients admitted to hospital with SARS-CoV-2 infection
Variable No. of patients No. (% total) of patients who died HR (95% CI) Crude Adjusted* Age group, yr < 70 229 17 (7.4) 1.0 1.0 70–79 123 25 (20.3) 1.77 (0.95–3.28) 1.37 (0.73–2.58) ≥ 80 298 111 (37.2) 3.58 (2.15–5.98) 2.39 (1.35–4.24) Sex Female 346 69 (19.9) 1.0 1.0 Male 304 84 (27.6) 1.42 (1.03–1.95) 1.74 (1.25–2.41) No. of comorbidities 0–1 221 20 (9.0) 1.0 1.0 2–3 253 65 (25.7) 2.09 (1.26–3.45) 1.47 (0.87–2.47) ≥ 4 176 68 (38.6) 3.36 (2.04–5.54) 2.01 (1.18–3.42) Living in residential care Patients not living in residential care 351 44 (12.5) 1.0 1.0 Patients living in residential care 299 109 (36.4) 2.39 (1.68–3.40) 1.62 (1.09–2.39) Note: CI = confidence interval, HR = hazard ratio.
↵* Model adjusted for age, sex, number of comorbidities and residential care status.
In this issue
Article tools
Respond to this article
Related Articles
Cited By...
- No citing articles found.